Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 7,009 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of the PhageTech Virus BioResistor

NCT04756284
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
PhageTech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 17, 2026, 5:23 AM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures

NCT03258658
View directory record Official record
Conditions
Urologic Diseases, Male Urogenital Diseases, Urethral Stricture, Urethral Injury
Interventions
Autologous Engineered Urethral Construct
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 75 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
San Francisco, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Dietary Acid Load, Kidney Function and Disability in Elderly

NCT02691663
View directory record Official record
Conditions
Chronic Kidney Disease, Disability
Interventions
Oral bicarbonate supplementation, Placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 17, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

NCT02947152
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Renal Cell Carcinoma
Interventions
HKT288
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

BRINK (BRain In Kidney Disease) Memory Study 2.0

NCT04975464
View directory record Official record
Conditions
Chronic Kidney Diseases, Dementia, Dementia, Vascular, Stroke, Alzheimer Disease, Cognitive Decline, Cognitive Impairment, Cognitive Dysfunction, Kidney Diseases, Diabetes, Cerebral Atrophy, Small Vessel Ischemic Disease
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

NCT06284564
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Evolocumab, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
View directory record Official record
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting No phase listed Observational

A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System

NCT07225933
View directory record Official record
Conditions
Urolithiasis, Kidney Stone, Kidney Stones
Interventions
CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)
Device
Lead sponsor
Calyxo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

NCT03597464
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00002733
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes, cimetidine
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Belimumab for Lupus Nephritis

NCT02260934
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT06708949
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear Cell
Interventions
Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Durham, North Carolina • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

NCT02112071
View directory record Official record
Conditions
Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

Promoting Increases in Living Donation Via Tele-navigation (PILOT)

NCT05468463
View directory record Official record
Conditions
Kidney Diseases
Interventions
Living Donor Navigator Program
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Not listed Phase 2 Interventional

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

NCT00717587
View directory record Official record
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 17, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

NCT05931393
View directory record Official record
Conditions
RCC, Renal Cell Carcinoma
Interventions
Cabozantinib 80 MG
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 17, 2026, 5:23 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852
View directory record Official record
Conditions
Glomerulonephritis, Membranous
Interventions
Belimumab 10 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

Mobility and Voiding Exercises in Older Women With Urinary Incontinence (MoVEonUp)

NCT05375344
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
Exercise Group
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
70 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples

NCT00001814
View directory record Official record
Conditions
Neoplastic Syndromes, Hereditary, Urologic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

NCT01582204
View directory record Official record
Conditions
Renal Cancer
Interventions
124IcG250
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Oxalate Formation From Ascorbic Acid

NCT04603898
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet, Carbon-13 Ascorbic Acid Oral Load
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

SARS-COV-2 Screening in Dialysis Facilities

NCT05225298
View directory record Official record
Conditions
End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease, Dialysis; Complications
Interventions
Offering SARS-CoV-2 test
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 17, 2026, 5:23 AM EDT